rs11039149

A pharmacogenomics study of 456 hypertensive participants examining whether fasting glucose GWAS variants predict glucose response to antihypertensive medications. The primary finding was that PROX1 rs340874 (C allele) was significantly associated with greater glucose elevation after 9 weeks of atenolol monotherapy (p=0.0013, beta = +2.39 mg/dL per allele). Two additional SNPs showed nominal associations: ARAP1 rs11603334 with atenolol response and SLC2A2 rs11920090 with HCTZ response.

In 1,574 subjects of European ancestry at high risk for type 2 diabetes, genetic variation in the NR1H2 gene (encoding liver X receptor β) was associated with impaired insulin secretion. The SNP rs2248949 showed significant association with insulin secretion during IVGTT (p=0.007) in a dominant model, with minor allele carriers showing 26% reduced insulin secretion. NR1H2 rs1405655 was also associated with first-phase insulin secretion (p=0.003), and NR1H3 rs11039149 associated with proinsulin conversion to insulin.